MNG1075
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.545
- NOTCH_SIGNALING+0.227
- ADIPOGENESIS+0.218
- FATTY_ACID_METABOLISM+0.176
- MYOGENESIS+0.173
- ANGIOGENESIS+0.152
- GLYCOLYSIS+0.138
- IL6_JAK_STAT3_SIGNALING+0.137
- APICAL_SURFACE+0.136
- COAGULATION+0.130
Top 10 suppressed
- E2F_TARGETS-0.477
- G2M_CHECKPOINT-0.412
- MYC_TARGETS_V1-0.307
- APOPTOSIS-0.285
- UV_RESPONSE_DN-0.262
- MYC_TARGETS_V2-0.247
- MITOTIC_SPINDLE-0.239
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.218
- INTERFERON_ALPHA_RESPONSE-0.205
- PROTEIN_SECRETION-0.199
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG367 | — | — | 0.702 |
| 2 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.701 |
| 3 | MNG877 | — | — | 0.695 |
| 4 | MNG756 | — | — | 0.687 |
| 5 | MNG62 | — | — | 0.681 |
| 6 | TCGA-49-4510-01A-01R-1206-07 | — | cohortA2 | 0.678 |
| 7 | TCGA-OR-A5JD-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Oncocytic Type | 0.678 |
| 8 | s0094283 | — | — | 0.677 |
| 9 | SRR5088845 | — | — | 0.671 |
| 10 | 6a2c6371-d8c6-4ca0-9a25-da16ed281d60 | — | — | 0.671 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.545 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.227 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.218 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.176 | Inavolisib | — uncovered |
| MYOGENESIS | 0.173 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.152 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.138 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.137 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.136 | Temsirolimus | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.104 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| HYPOXIA | 0.097 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.077 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.076 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.064 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.054 | Inavolisib | — uncovered |
| COMPLEMENT | 0.042 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.041 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.004 | Remibrutinib | — uncovered |